**BRCA1**<sup>185delAG</sup> tumors may acquire therapy resistance through expression of RING-less BRCA1

Rinske Drost,1 Kiranjit K. Dhillon,2 Hanneke van der Gulden,1 Ingrid van der Heijden,1 Inger Brandsma,3 Cristina Cruz,4,5 Dafni Chondronasiou,1 Marta Castroviejo-Bermejo,4 Ute Boon,1 Eva Schut,1 Eline van der Burg,1 Ellen Wientjens,1 Mark Pieterse,1 Christiaan Klijn,1 Sjoerd Klarenbeek,1 Fabricio Loayza-Puch,6 Ran Elkon,6 Liesbeth van Deemter,1 Sven Rottenberg,1,7 Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 3Department of Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands. 4Experimental Therapeutics Group and J Clin Invest. Accepted: March 29, 2013; Submitted: May 9, 2016.

The authors have declared that no conflict of interest exists.

Introduction

Breast cancer is one of the most common malignancies in women, accounting for almost 1 in 3 diagnosed cancers, and it is the second leading cause of cancer death among women in Western countries (1). Five percent to ten percent of all breast cancer cases have a hereditary component, and thirty percent to eighty percent of all hereditary cases are attributable to mutations in the breast cancer 1 (BRCA1) or breast cancer 2 (BRCA2) gene. Germline mutations in the BRCA1 gene predispose women to hereditary breast and ovarian cancer (HBOC), with an 80%–90% lifetime risk of developing breast cancer and a 40%–50% risk of developing ovarian cancer (2).

Germline BRCA1 mutations are scattered throughout the 81-kb-long gene that encompasses 22 coding exons (3). Most of the known pathogenic BRCA1 mutations are predicted to result in premature termination of protein translation and nonsense-mediated mRNA decay (NMD) (4, 5). These mutations include small deletions and insertions that generate frameshifts, single-base substitutions that produce termination codons, and splice site errors (2). Although there are many different BRCA1 mutations, in certain ethnic populations, only a few founder mutations account for almost all BRCA1-associated breast and/or ovarian cancer families. Two founder mutations, **BRCA1**<sup>185delAG</sup> and **BRCA1**<sup>5382insC</sup>, account for the vast majority of BRCA1 mutations in the Ashkenazi Jewish population (2, 6). The **BRCA1**<sup>185delAG</sup> and **BRCA1**<sup>5382insC</sup> mutations are carried, respectively, by 1% and 0.15% of Ashkenazi Jews (7, 8). The prevalence of these mutations in unselected patients of Ashkenazi Jewish ethnicity who have ovarian cancer was found to be close to 30% and may even exceed 50% in patients with a family history of breast and/or ovarian cancer (9–11).

BRCA1 has been implicated in various cellular processes, including DNA repair, cell-cycle control, and transcriptional regulation (12). In particular, the role of BRCA1 in homologous recombination-mediated (HR-mediated) repair of DNA double-strand breaks (DSBs) appears to be important in the maintenance of genomic stability and tumor suppression (13). Impaired HR also renders BRCA1-deficient cells extremely sensitive to DSB-inducing agents, like platinum drugs (14). In line with this, patients

**Related Commentary: p. 2802**

Conflict of Interest: The authors have declared that no conflict of interest exists. Submitted: March 29, 2013. Accepted: May 9, 2016. Reference information: J Clin Invest. 2016;126(8):2903–2918. doi:10.1172/JCI70196.
with BRCA1-mutated ovarian cancer had a better prognosis after platinum-based chemotherapy than did nonmutation carriers (15–18). More recently, it was also shown that triple-negative breast cancers in BRCA1 mutation carriers were highly sensitive to neoadjuvant cisplatin chemotherapy (19). Moreover, patients harboring breast tumors with a BRCA1-like genomic profile had a significantly greater benefit from high-dose, platinum-based chemotherapy versus conventional chemotherapy than did patients with non-BRCA1-like tumors (20). Also, chemical inhibitors of poly(ADP-ribose) polymerase (PARP), an enzyme involved in DNA single-strand break (SSB) repair, are effective against BRCA-deficient tumors in preclinical models (21–23) and in patients carrying BRCA2 mutations (24–29). Recently, the clinical PARP inhibitor olaparib (Lynparza) has been approved as maintenance therapy for BRCA mutation carriers with platinum-sensitive ovarian cancer (30). PARP inhibition results in an increased number of DSBs due to replication fork collapse at SSBs. PARP inhibition is therefore selectively toxic in cells that lack HR-mediated DSB repair, such as BRCA1/2-deficient tumor cells.

The BRCA1 gene encodes for a protein of 1863 aa that contains a highly conserved amino-terminal really interesting new gene (RING) domain and tandem BRCA1 C-terminus domain (BRCT) repeats at its carboxyl terminus (31). The RING domain of BRCA1 is required for stable interaction with BRCA1-associated RING domain 1 (BARD1), and the BRCA1/BARD1 heterodimer has E3 ubiquitin ligase activity with the class of UBCH5 E2 ubiquitin-conjugating enzymes (32, 33). The observation that BRCA1/BARD1-dependent ubiquitin conjugates occur at DSBs suggests that the BRCA1/BARD1 heterodimer is important for DNA repair and thereby for the tumor-suppressive function of BRCA1 (34). BRCA1 has been reported to interact with numerous other proteins involved in DNA repair, cell-cycle checkpoint control, transcription, and chromatin remodeling, mainly through its BRCT domains (35–40).

Recent studies have shown that not all biochemical activities of BRCA1 are equally important for its role in tumor suppression and therapy response (41). Using genetically engineered mouse models, Shakya and coworkers showed that loss of BRCA1 E3 ligase activity does not lead to tumor formation, while loss of BRCT phosphoprotein binding does (42). We showed that BRCA1 RING function is essential for tumor suppression, but does not lead to hypersensitivity to homologous recombination deficiency–targeting (HRD-targeting therapy (43). Mouse mammary tumors that express a mutant BRCA1-C661G protein, which lacks a functional RING domain, respond much worse to DSB-inducing therapy than do Brca1-null tumors. In addition, tumors carrying the Brca1<sup>C661G</sup> mutation rapidly develop therapy resistance, while retaining the Brca1 mutation. These data suggest that the mutant BRCA1-C661G protein has some residual activity in the DNA damage response. This may not only hold true for the BRCA1<sup>C661G</sup> missense mutation, but also for other BRCA1 mutations, and could indicate the existence of differences in therapeutic response and resistance between different BRCA1 mutation carriers.

In the present study, we investigated the effects of the 2 most common BRCA1 frameshift mutations, BRCA1<sup>185delAG</sup> and BRCA1<sup>5382stop</sup>, on tumor development and therapy response and resistance in genetically engineered mouse models.

**Results**

**Generation of Brca1<sup>185delAG</sup> and Brca1<sup>5382stop</sup> alleles.** In order to mimic the human BRCA1<sup>185delAG</sup> and BRCA1<sup>5382stop</sup> mutations in mice, we used short, synthetic, single-stranded oligodeoxyribonucleotides to introduce mutations into the genome of mouse embryonic stem cells (mESCs). It has previously been shown that this technique requires (transient) suppression of DNA mismatch repair (MMR) by knockdown of Mlh1 or knockout of Msh2 or Msh3 (44–47). In order to mimic the BRCA1<sup>185delAG</sup> mutation, we introduced the Brca1<sup>185delAG</sup> mutation into Mlh1-knockdown mESCs by substitution of 3 nucleotides (TCC to AAG), thereby creating an early STOP codon at aa 24 (Figure 1A). We used Msh3-knockout mESCs to insert 4 nucleotides (AGGA) to generate the Brca1<sup>5382stop</sup> mutation, which resulted in premature protein truncation at aa 1713 and closely resembled the human BRCA1<sup>5382stop</sup> mutation (Figure 1B). Brca1<sup>185delAG</sup> and Brca1<sup>5382stop</sup> mutant mESCs were injected into 3.5-day-old C57BL/6J blastocysts to generate chimeric mice. Chimeric mice were mated with FVB female mice, and germline transmission of the mutant alleles was verified by melting-curve genotyping, PCR, and sequencing (Figure 1, C and D, and data not shown).

**Embryonic lethality of homozygous Brca1<sup>185delAG</sup> and Brca1<sup>5382stop</sup> mice.** To determine the effect of the Brca1<sup>185delAG</sup> and Brca1<sup>5382stop</sup> mutations on normal mouse development, we intercrossed heterozygous Brca1<sup>185delAG</sup> or Brca1<sup>5382stop</sup> mice to produce homozygous offspring. No homozygous pups were born (Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI70196DS1), indicating that homozygous Brca1<sup>185delAG</sup> or Brca1<sup>5382stop</sup> mutations lead to embryonic lethality. To study at which stage of embryonic development homozygous Brca1<sup>185delAG</sup> and Brca1<sup>5382stop</sup> mice die, embryos were harvested and genotyped at several time points after gestation. Although (resorbed) homozygous Brca1<sup>185delAG</sup> and Brca1<sup>5382stop</sup> embryos could still be recovered from E12.5 to E13.5 (Supplemental Table 1), they were already severely delayed in development at E15.5 compared with WT and heterozygous embryos (Figure 1, E and F).

**Mammary tumor development in K14-Cre Brca1<sup>185delAG</sup> p53<sup>fl/fl</sup> and K14-Cre Brca1<sup>5382stop</sup> p53<sup>fl/fl</sup> mice.** To investigate the influence of Brca1<sup>185delAG</sup> and Brca1<sup>5382stop</sup> mutations on tumor development, we independently introduced both alleles into the K14-Cre<sup>fl/fl</sup> p53<sup>fl/fl</sup> mouse model (referred to hereafter as KB1P mouse model, in which epithelium-specific deletion of Brca1<sup>185delAG</sup> or Brca1<sup>5382stop</sup> alleles predisposes mice to mammary and skin tumor formation (48). The resulting mice carry 1 Brca1<sup>185delAG</sup> or 1 Brca1<sup>5382stop</sup> allele throughout their body and sporadically lose the remaining Brca1 WT allele in specific tissues, including mammary gland. We crossed heterozygous Brca1<sup>185delAG</sup> and Brca1<sup>5382stop</sup> mice with K14 mice to generate cohorts of K14-Cre Brca1<sup>185delAG</sup> p53<sup>fl/fl</sup> mice [referred to hereafter as KB1(185stop)P mice], K14-Cre Brca1<sup>5382stop</sup> p53<sup>fl/fl</sup> [referred to hereafter as KB1(5382stop)P mice], and Brca1<sup>185delAG</sup> and Brca1<sup>5382stop</sup> littermate controls. The 3 cohorts were monitored for spontaneous tumor formation and showed equal rates of tumor-free survival (TFS) (Figure 2A). For all cohorts, the median TFS was approximately 200 days, which is similar to what has been described previously for KB1 mice (48) and for mice carrying the Brca1<sup>C661G</sup> mutation (43). In addition, no obvious differences in TFS could be detected between cohorts when only mammary tumors (Figure 2B) or skin tumors (Supplemental Figure 1A) were taken into account. Mammary and
mammary tumors that developed in \( KB1(185\text{stop})P \), \( KB1(5382\text{stop})P \), and \( KB1P \) mice were grouped as lumen-forming carcinomas with varying degrees of glandular differentiation (Figure 2C and Supplemental Figure 1, E and F). Like the majority of human \( BRCA1 \)–mutated breast cancers (49), most \( KB1(185\text{stop})P \) and \( KB1(5382\text{stop})P \) mammary tumors stained negative for the estrogen receptor (Supplemental Figure 1, G and H, and Supplemental Table 2).

A high level of genomic instability is one of the hallmarks of human \( BRCA1 \)–associated breast cancer (50), and \( BRCA1 \)-deficient mouse mammary tumors display a considerably larger number of genetic aberrations than do \( BRCA1 \)-proficient tumors (43, 48, 51). To investigate the level of genomic instability in \( KB1(185\text{stop})P \) and \( KB1(5382\text{stop})P \) tumors, we measured DNA copy number aberrations (CNAs) in mammary tumors from \( KB1(185\text{stop})P \) (\( n = 20 \)), skin TFS rates were comparable between \( KB1P \) mice derived from the 185delAG cohort and from the 5382insC cohort (Supplemental Figure 1, B and C). Furthermore, the spectrum and incidence of tumors that developed were similar among \( KB1(185\text{stop})P \), \( KB1(5382\text{stop})P \), and \( KB1P \) mice (Supplemental Figure 1D).

Characterization of \( KB1(185\text{stop})P \) and \( KB1(5382\text{stop})P \) mammary tumors. On the basis of their histomorphological characteristics, the majority of mammary tumors that developed in \( KB1(185\text{stop})P \) (84%), \( KB1(5382\text{stop})P \) (79%), and \( KB1P \) mice (85%) were classified as poorly differentiated, solid carcinomas (Figure 2C and Supplemental Figure 1, E and F). In line with this observation, most \( KB1(185\text{stop})P \) and \( KB1(5382\text{stop})P \) mammary tumors stained (partially) positive for the epithelial marker cytokeratin 8 and negative for the mesenchymal marker vimentin (Supplemental Figure 1, G and H, and Supplemental Table 2). In all cohorts, only a small fraction of mammary tumors (8%) was classified as carcinosarcoma, characterized by the presence of spindle-shaped cells (Figure 2C and Supplemental Figure 1, E and F). Other mammary tumors that developed in \( KB1(185\text{stop})P \), \( KB1(5382\text{stop})P \), and \( KB1P \) mice were grouped as lumen-forming carcinomas with varying degrees of glandular differentiation (Figure 2C and Supplemental Figure 1, E and F). Like the majority of human \( BRCA1 \)-mutated breast cancers (49), most \( KB1(185\text{stop})P \) and \( KB1(5382\text{stop})P \) mammary tumors stained negative for the estrogen receptor (Supplemental Figure 1, G and H, and Supplemental Table 2).

A high level of genomic instability is one of the hallmarks of human \( BRCA1 \)-associated breast cancer (50), and \( BRCA1 \)-deficient mouse mammary tumors display a considerably larger number of genetic aberrations than do \( BRCA1 \)-proficient tumors (43, 48, 51). To investigate the level of genomic instability in \( KB1(185\text{stop})P \) and \( KB1(5382\text{stop})P \) tumors, we measured DNA copy number aberrations (CNAs) in mammary tumors from \( KB1(185\text{stop})P \) (\( n = 20 \),
reached a volume of 200 mm$^3$, tumor-bearing mice were treated with 50 mg/kg of the PARP inhibitor olaparib (AZD2281) for 28 consecutive days or left untreated (Figure 3A).

We did not observe any differences in overall survival (OS) between mice that did not receive treatment; all mice had to be sacrificed within 25 days because of a large tumor (Figure 3B and Supplemental Figure 2). The KP and KB1P data have been published before (43). While mice carrying KP tumors did not respond at all to olaparib treatment (Figure 3, C and D; black curves; median OS $[t_{50}] = 10$ days), the median OS of mice carrying KB1P tumors increased from 12 to 60 days following olaparib treatment, and their tumors disappeared completely during the course of treatment (Figure 3, C and D; red curves). However, KB1P tumors could not be fully eradicated with this 28-day olaparib dosing schedule, and tumors reappeared after the end of the treatment period.

The median OS of mice transplanted with KB1(5382stop)P tumors increased from 8 to 52 days after olaparib treatment (Figure 3, B and C; blue curves), which was significantly better than the median OS of mice transplanted with KP tumors [KB1(5382stop)P vs. KP, $P < 0.0001$, log-rank test]. No significant difference in OS was observed between mice with KB1(5382stop)P tumors and those KB1(185stop)P tumors to the PARP inhibitor olaparib. PARP inhibitors have been shown to be effective in breast and ovarian cancer patients carrying BRCA1/2 mutations (24–28). To study the response of KB1(185stop)P and KB1(5382stop)P tumors to PARP inhibition, we transplanted several independent KB1(185stop)P, KB1(5382stop)P, BRCA1-deficient KB1P, and BRCA1-proficient K14-Cre p53$^{fl/fl}$ (referred to hereafter as KP) tumors into the fourth mammary gland of syngeneic female recipient mice. This orthotopic transplantation model ensures that transplanted mouse mammary tumors retain the histomorphological features, molecular characteristics, and drug-sensitivity profiles of their spontaneous counterparts (54, 55). When tumors

KB1(5382stop)P ($n = 20$), and littermate control KB1P mice ($n = 22$) using array comparative genomic hybridization (aCGH). When applying the comparative module of the R package KCsmart (52, 53), we did not detect any differences between recurrent CNAs in KB1(185stop)P or KB1P tumors (Figure 2D). We also could not find any differences in recurrent CNAs between KB1(5382stop)P and KB1P tumors (Figure 2E). On the basis of these results, we conclude that the histological and genetic features of KB1(185stop)P and KB1(5382stop)P mammary tumors are indistinguishable from each other and from those of KB1P control tumors.

Response of KB1(185stop)P mammary tumors to the PARP inhibitor olaparib. PARP inhibitors have been shown to be effective in breast and ovarian cancer patients carrying BRCA1/2 mutations (24–28). To study the response of KB1(185stop)P and KB1(5382stop)P tumors to PARP inhibition, we transplanted several independent KB1(185stop)P, KB1(5382stop)P, BRCA1-deficient KB1P, and BRCA1-proficient K14-Cre p53$^{fl/fl}$ (referred to hereafter as KP) tumors into the fourth mammary gland of syngeneic female recipient mice. This orthotopic transplantation model ensures that transplanted mouse mammary tumors retain the histomorphological features, molecular characteristics, and drug-sensitivity profiles of their spontaneous counterparts (54, 55). When tumors
with KBIP tumors after treatment with olaparib [KB1(5382stop)P vs. KBIP, P = 0.0905 (NS), log-rank test]. However, in contrast to KBIP tumors, KB1(5382stop)P tumors never completely disappeared during olaparib treatment, but rather entered a phase of tumor stasis (Figure 3D; blue curve).

Interestingly, mice transplanted with KB1(185stop)P tumors had a median OS of 26 days after the start of olaparib treatment (Figure 3C; green curve), which was significantly better than for mice with BRCA1-proficient KP tumors [KB1(185stop)P vs. KP, P = 0.0017, log-rank test], but significantly worse than for mice with BRCA1-deficient KBIP tumors [KB1(185stop)P vs. KBIP, P < 0.0001, log-rank test]. While KB1(185stop)P tumors kept growing during the course of olaparib treatment, their growth rate was reduced compared with that of KP tumors (Figure 3D; green curve). Moreover, the olaparib response of KB1(185stop)P tumors was markedly worse than the response of KB1(5382stop)P tumors [Figure 3, C and D and Supplemental Figure 2; KB1(185stop)P vs. KB1(5382stop)P, P = 0.0012, log-rank test]. The response of KB1(185stop)P tumors to olaparib treatment closely resembled the response of K14-Cre Brca1C61Gp53/Gp (referred to hereafter as KB1C61GP) mouse mammary tumors to olaparib (43).

Response of KB1(185stop)P mammary tumors to cisplatin. Since BRCA1-associated tumors are also known to be sensitive to platinum drugs (56), we transplanted several KB1(185stop)P, KB1(5382stop)P, KBIP, and BRCA1-proficient KP mammary tumors to study potential differences in their response to cisplatin (Supplemental Table 3). Tumor-bearing mice were injected with the maximal tolerable dose of cisplatin and re-treated every 2 weeks when the tumor volume was more than 50% of the starting volume. If the tumor size after 2 weeks was smaller than 50%, treatment was postponed until the tumor reached 100% of the starting volume (Figure 4A). As some animals had to be sacrificed because of the toxic side effects of multiple cisplatin doses, we measured OS as well as TFS rates. Again, the data on the KP and KBIP controls have been previously published (43).

The median OS of mice transplanted with KB1(5382stop)P tumors was prolonged from 8 to 159 days after cisplatin treatment (Figure 4, B and C; blue curves), which is identical to the response of mice transplanted with BRCA1-deficient KBIP tumors (43) [Figure 4, B and C; red curves, KB1(5382stop)P vs. KBIP; P = 0.9696 (NS), log-rank test]. Almost all mice transplanted with KB1(5382stop)P tumors had to be sacrificed because of cisplatin toxicity and not because of therapy resistance (Figure 4D). In contrast, the median OS of mice transplanted with KB1(185stop)P mammary tumors was only prolonged from 15 to 55 days after treatment with cisplatin (Figure 4, B and C; green curves) and was indistinguishable from the response of BRCA1-proficient tumors [Figure 4, B and C; black curves, KB1(185stop)P vs. KP, P = 0.2550 (NS), log-rank test]. After an initial response to cisplatin, KB1(185stop)P tumors rapidly acquired resistance, and 62% of the mice needed to be sacrificed because of therapy-resistant tumors (Figure 4D). Remarkably, the response of KB1(185stop)P tumors
to cisplatin was significantly worse than that of KB1(5382stop)P tumors [Figure 4C; KB1(185stop)P vs. KB1(5382stop)P, P < 0.0001, log-rank test; Supplemental Figure 3, A–E]. The difference in response to cisplatin was even more pronounced when we compared the TFS of mice transplanted with KB1(185stop)P or KB1(5382stop)P mammary tumors (Supplemental Figure 3F).

To investigate whether these findings might also be relevant for human patients, we evaluated the cisplatin sensitivity of several human BRCA1-mutant breast cancer cell lines. These included the SUM1315MO2 and HCC1937 cell lines, which carry BRCA1<sup>185delAG</sup> and BRCA1<sup>5382insC</sup> mutations, respectively. In line with our observations in the mouse models, BRCA1<sup>185delAG</sup>-mutant SUM1315MO2 human breast cancer cells were less sensitive to cisplatin than were other BRCA1-mutated human breast cancer cell lines, including the BRCA1<sup>5382insC</sup>-mutant HCC1937 cell line (Figure 4E). However, BRCA1<sup>185delAG</sup>-mutant SUM1315MO2 cells were more sensitive to cisplatin than were BRCA1-proficient U2OS cells or WT BRCA1–complemented HCC1937 cells (Figure 4E).
Therapy resistance of mouse and human BRCA$^{185\text{delAG}}$ tumor cells is not explained by genetic reversion or loss of 53BP1. Given that BRCA1/2-deficient cell lines and ovarian tumors can become resistant to platinum compounds and olaparib through genetic reversion of the BRCA1/2 mutation (57–60), we first checked whether the Brca1$^{185\text{stop}}$ mutation was still present in platinum-resistant KB1(185stop)$^P$ tumors. Previously, we did not find any evidence for secondary Brca1 mutations in therapy-resistant KB1C61GP tumors (43). Similarly, Sanger sequencing and melting-curve genotyping revealed that all cisplatin-resistant KB1(185stop)$^P$ tumors had retained the Brca1$^{185\text{stop}}$ mutation (Supplemental Figure 4A and data not shown). On the basis of these results, we conclude that the observed platinum resistance in KB1(185stop)$^P$ mammary tumors is not caused by genetic reversion of the Brca1$^{185\text{stop}}$ mutation. Furthermore, we were able to derive several cisplatin-resistant clones of the BRCA1-mutated human breast cancer cell line SUM1315MO2, all of which also retained the BRCA1$^{185\text{delAG}}$ mutation (Supplemental Figure 4, B–D). In the absence of genetic reversion, loss of 53BP1 may also decrease the sensitivity of BRCA1-deficient mouse mammary tumors to olaparib and cisplatin (61). However, loss of 53BP1 does not explain the poor treatment response of the KB1(185stop)$^P$ mouse model, as platinum-resistant and treatment-naive tumors all showed abundant expression of 53BP1 (Supplemental Figure 4, D and E, and data not shown).

RING-less BRCA1 expression in mouse and human BRCA$^{185\text{delAG}}$ tumor cells. Since the response of KB1(185stop)$^P$ mouse mammary tumors to olaparib and cisplatin is similar to that of BRCA1-proficient KP tumors, we analyzed BRCA1 protein expression in KB1(185stop)$^P$ mouse mammary tumor cell lines. As controls, SUM1315MO2 cells stably complemented with WT BRCA1 (WT) were depleted of endogenous BRCA1 by a BRCA1 3’-UTR-targeting shRNA (sh1) or depleted of both endogenous and ectopic BRCA1 using an shRNA targeting BRCA1 exon 11 (sh2). shNT, NT shRNA. Expression of POLII was used as a loading control, and the positions of full-length and RING-less BRCA1 and protein size markers are indicated. hBRCA1, human BRCA1. (C) Ribosome profiling of KB1(185stop)$^P$ mammary tumor cell lines indicated a translation start at methionine 90. Ribosome footprint profile along Brca1 exons 2 (containing methionine 1) and 6 (containing methionines 90 and 99) of 2 different KB1(185stop)$^P$ mouse mammary tumor cell lines (lines 280 and 350) and a KP control. Methionines are indicated in green. Harr., harringtonine; M1, methionine 1; M90, methionine 90. (D) Schematic representations of BRCA1 peptides identified by mass spectrometry in Brca1 WT and KB1(185stop)$^P$ mouse mammary tumor cells.

Figure 5. RING-less BRCA1 expression in mouse and human BRCA$^{185\text{delAG}}$ tumor cells. (A) BRCA1 protein expression in KB1(185stop)$^P$ mouse mammary tumors (left panel) compared with BRCA1-deficient KB1(5382stop)$^P$ and KB1P tumors (middle panels). A BRCA1-proficient KP tumor was used as a positive control (right panel). The asterisk in the far right panel indicates another KB1(185stop)$^P$ mouse mammary tumor. Expression of POLII was used as a loading control, and the positions of full-length (FL) and RING-less (ΔRING) BRCA1 and protein size markers are indicated. mBRCA1, murine BRCA1. (B) BRCA1 protein expression in the BRCA1$^{185\text{delAG}}$-mutant SUM1315MO2 human breast cancer cell line. As controls, SUM1315MO2 cells stably complemented with WT BRCA1 (WT) were depleted of endogenous BRCA1 by a BRCA1 3’-UTR-targeting shRNA (sh1) or depleted of both endogenous and ectopic BRCA1 using an shRNA targeting BRCA1 exon 11 (sh2). shNT, NT shRNA. Expression of POLII was used as a loading control, and the positions of full-length and RING-less BRCA1 and protein size markers are indicated. hBRCA1, human BRCA1. (C) Ribosome profiling of KB1(185stop)$^P$ mammary tumor cell lines indicated a translation start at methionine 90. Ribosome footprint profile along Brca1 exons 2 (containing methionine 1) and 6 (containing methionines 90 and 99) of 2 different KB1(185stop)$^P$ mouse mammary tumor cell lines (lines 280 and 350) and a KP control. Methionines are indicated in green. Harr., harringtonine; M1, methionine 1; M90, methionine 90. (D) Schematic representations of BRCA1 peptides identified by mass spectrometry in Brca1 WT and KB1(185stop)$^P$ mouse mammary tumor cells.
We therefore checked BRCA1 protein expression levels in the SUM1315MO2 human breast cancer cell line, which carries the BRCA1<sup>185delAG</sup> mutation. Remarkably, in BRCA1<sup>185delAG</sup>-mutant SUM1315MO2 cells, BRCA1 immunoblotting also detected a large protein that could be completely depleted using BRCA1-specific shRNAs (Figure 5B). In contrast to the truncated BRCA1 formed by KBI<sup>185stop</sup>P tumor cells, the BRCA1 protein expressed by SUM1315MO2 cells was clearly smaller than full-length WT BRCA1, indicating the absence of a substantial part of the protein. In addition, we could not detect the truncated protein with a BRCA1 Ab that binds the extreme N-terminus of BRCA1 (aa 1-304; Supplemental Figure 5A). Together, these findings show that the BRCA1<sup>185delAG</sup> mutation can lead to production of a mutant BRCA1-ΔRING protein, which is probably devoid of its N-terminal RING domain (aa 1-109).

Whether the truncated BRCA1 variant expressed by KBI<sup>185stop</sup>P tumor also lacks the RING domain cannot be deduced from the minimal size difference observed with full-length BRCA1. In the absence of Abs of sufficient quality to distinguish between full-length and RING-less mouse BRCA1 protein, we performed ribosome profiling of cell lines derived from treatment-naive KBI<sup>185stop</sup>P and Brca1 WT KP mouse mammary tumors. We used harringtonine treatment to enrich for ribosomes at sites of translation initiation (63) and observed increased use of internal methionine 90 in KBI<sup>185stop</sup>P mouse mammary tumor cells compared with KP cells (Figure 5C). Since these data suggest that the nearly full-length BRCA1 protein expressed in KBI<sup>185stop</sup>P mouse mammary tumors also lacks the RING domain, mass spectrometric experiments were performed to verify the loss of the RING domain.

BRCA1 protein was immunoprecipitated using an Ab raised against aa 1238-1812 (64) and analyzed after size selection by denaturing polyacrylamide gel electrophoresis. Whereas BRCA1-RING (aa 1-109) peptides were readily identified in WT BRCA1-expressing mouse tumor cells, they were not found in 2 different cell lines derived from KBI<sup>185stop</sup>P tumors (Figure 5D, Supplemental Figure 5B, and Supplemental Table 4). These data are compatible with the expression of RING-less BRCA1 in KBI<sup>185stop</sup>P cells. Given that even in WT BRCA1-expressing cells, not all possible RING peptides could be detected by mass spectrometry, the precise composition of BRCA1-ΔRING variants could not be determined (Figure 5D and Supplemental Figure 5B). However, analysis of the most N-terminal peptides identified supports a translation start at methionine 90, as suggested by ribosome profiling.

To test whether resistance in KBI<sup>185stop</sup>P tumors was due to increased expression of BRCA1-ΔRING, we analyzed Brca1 mRNA and BRCA1-ΔRING protein levels. Although we found significantly increased Brca1 mRNA levels in most platinum-resistant KBI<sup>185stop</sup>P tumors compared with levels in untreated tumors (Supplemental Figure 5C), we did not find a consistent concomitant increase in RING-less BRCA1 protein levels (Supplemental Figure 5D). Moreover, expression of RING-less BRCA1 protein was also not significantly increased in SUM1315MO2 clones that had been selected for increased resistance to cisplatin (Supplemental Figure 5A). These findings imply that upregulation of RING-less protein expression is not strictly required for BRCA1<sup>185delAG</sup>-mutant tumor cells to become resistant to platinum therapy. Nevertheless, expression of RING-less BRCA1 distinguishes KBI<sup>185stop</sup>P tumors from KBIP tumors and most likely explains the poor response to HRD-targeted therapy.

DNA damage response in mouse and human BRCA1<sup>185delAG</sup> tumor cells. The absence of genetic reversion of Brca1 or loss of 53BP1 in platinum-resistant KBI<sup>185stop</sup>P tumors suggests that RING-less BRCA1 protein has residual activity in the cellular response to DNA DSBs. In line with our observation that KBI<sup>185stop</sup>P tumors showed some response to PARP1 inhibition, treatment with olaparib resulted in a DNA-damage increase similar to that seen in KBIP tumors (Figure 6A). However, we also found that the response to olaparib was eventually poor compared with that of KBIP tumors that were completely devoid of BRCA1 protein expression. To investigate whether RING-less BRCA1 protein has activity in DNA DSB repair via HR, we compared the ability to form RAD51 irradiation-induced foci (IRIF) in short-term tumor cell cultures derived from KBI<sup>185stop</sup>P, KBIP, and BRCA1-proficient KP tumors. As shown previously (43), we could readily detect RAD51 IRIF in short-term cultures of HR-proficient KP tumor cells, but not in HR-deficient KBIP tumor cells (Figure 6, B and C). KBI<sup>185stop</sup>P tumor cells were also able to form RAD51 IRIF (Figure 6, B and C). Despite the statistically significant difference, the data from the short-term ex vivo cell-culture experiments were quite variable. To gain further insight into the DNA damage response of KBI<sup>185stop</sup>P tumors, we continued our analysis in mouse mammary tumor–derived cell lines. In agreement with the loss of BRCA1 function we observed, KBI<sup>185stop</sup>P cell lines had a defect in DNA end resection, as replication protein A (RPA) accumulation at DSBs was impaired (Figure 6D). Indeed, KBI<sup>185stop</sup>P cell lines showed an initial deficiency in the repair of olaparib-induced DNA damage that was similar to that in KBIP cells (Figure 6E). Nevertheless, KBI<sup>185stop</sup>P tumor cell lines showed RAD51 IRIF formation (Supplemental Figure 6A). In addition, human SUM1315MO2 breast cancer cells — carrying the BRCA1<sup>185delAG</sup> mutation — were also capable of forming RAD51 IRIF (Supplemental Figure 6B). Thus, both mouse and human BRCA1<sup>185delAG</sup> tumor cells display HR activity in response to DNA damage, which could be the result of BRCA1-ΔRING expression.

To study whether the RING-less BRCA1 protein is functional in the DNA damage response, we checked for colocalization of BRCA1 with RAD51 after γ-irradiation in cell lines derived from BRCA1-proficient, BRCA1-deficient, and Brca1<sup>185stop</sup> mouse mammary tumors. While massive BRCA1/RAD51 colocalization was observed in BRCA1-proficient tumor cells, Brca1<sup>185stop</sup> tumor cells showed fewer and smaller BRCA1/RAD51 IRIF (Supplemental Figure 6A and data not shown). In contrast, BRCA1-deficient KBIP B11 cells showed no BRCA1/RAD51 IRIF at all (Supplemental Figure 6A). These data suggest that the RING-less BRCA1 protein is partially functional in the response to DNA damage. This may explain why human and mouse BRCA1<sup>185delAG</sup> tumor cells rapidly develop resistance to therapy that targets their HRD.

RING-less BRCA1 supports DNA repair via HR, resulting in reduced sensitivity of BRCA1<sup>185delAG</sup> tumor cells to PARP1 inhibition and cisplatin. To test whether mutant RING-less BRCA1 protein is indeed functionally important for BRCA1<sup>185delAG</sup>-mutant tumor cells, we performed BRCA1-knockdown experiments. Expression of RING-less BRCA1 in BRCA1<sup>185delAG</sup>-mutant SUM1315MO2 cells was markedly reduced by transduction with lentiviruses encod-
able to complement SUM1315MO2 BRCA1\(^{185\text{delAG}}\)-mutant cells depleted of endogenous BRCA1 expression by shRNAi in a clonal growth assay (Figure 7C and Supplemental Figure 7F). These data show that BRCA1\(^{185\text{delAG}}\) cells are dependent on expression of the RING-less BRCA1 protein, possibly through its function in the repair of DNA DSBs.

To further analyze the effects of RING-less BRCA1 expression on treatment response, we used mouse KB1(185stop)P tumor cells, which were much less dependent on RING-less BRCA1 for proliferation than were SUM1315MO2 cells (data not shown). KB1(185stop)P tumor cell lines showed varying levels of sensitivity to olaparib and cisplatin, which seemed to correlate to some extent with expression levels of RING-less BRCA1 protein (Supplemental Figure 8, A and B). Similar to SUM1315MO2 cells, KB1(185stop)P tumor cells also showed decreased RAD51 IRIF formation upon knockdown of Brca1 expression (Supplemental Figure 8, C and D).

To obtain direct evidence of the functional activity of RING-less BRCA1 proteins, we generated a series of N-terminal truncation mutants of human BRCA1. Western blot analysis of these mutants suggests that the main human RING-less BRCA1 protein is formed by alternative translation initiation at methionine 297 (Supplemental Figure 7E). Interestingly, BRCA1-M297 also appeared to be abundantly produced by cDNA constructs encoding BRCA1-M48 and BRCA1-M128 (Supplemental Figure 7E). All N-terminal truncation variants of BRCA1 tested were

Figure 6. DNA damage response in mouse and human BRCA1\(^{185\text{delAG}}\) tumor cells. (A) Olaparib induced DNA damage in orthotopically transplanted KB1(185stop)P (185stop, n = 6), KB1P (n = 7), and KP (n = 6) tumors and nontreated controls (n = 4 for each genotype). Statistical significance was calculated using a 2-tailed, unpaired t test. (B) RAD51 IRIF in KB1(185stop)P, KB1P, and KP tumor cell suspensions. Nuclei (blue) with more than 10 RAD51 foci (red) are indicated with red arrowheads. Red outlined areas highlight single-cell zoom-in (zoom, \(\times 63\)). Scale bars: 25 \(\mu\)m. (C) Quantification of RAD51 IRIF in KB1(185stop)P (n = 5), KB1P (n = 10), and KP (n = 7) tumors. Percentages were normalized to KP. Statistical significance was calculated using a 2-tailed, unpaired t test. (D) Accumulation of RPA at α tracks for 2 different KB1(185stop)P mouse mammary tumor cell lines (lines 350 and 351) and KB1P and KP controls. At least 100 53BP1 tracks were evaluated per time point in 2 to 3 replicate experiments, and statistical significance at 2 hours was calculated using Fisher’s exact test. (E) Olaparib induced DNA damage in 2 different KB1(185stop)P mouse mammary tumor cell lines (lines 350 and 351) and KB1P and KP controls. Cells were cultured in normal medium (day 0 [D0]) or treated for 24 hours with 10 \(\mu\)M olaparib and either analyzed directly (D1) or after a 3-day recovery period (D3). Red bars indicate the mean number of 53BP1 foci in at least 120 cells, and data are representative of 2 independent experiments. Statistical significance was calculated using a 2-tailed, unpaired t test.
The Journal of Clinical Investigation

RESEARCH ARTICLE

2912

Evidence for the relevance of RING-less BRCA1 in therapy response. We targeted the BRCA1-BRCT-encoding region using a single-guide RNA (sgRNA) specific for exon 21 of Brca1. In 2 of 3 Kbi(185stop)P clones analyzed (clones C1 and C3), frameshift mutations in exon 21 of the Brca1185delAG allele resulted in loss of RING-less BRCA1 protein expression (Supplemental Figure 9, A and B). Similar to Brca1 knockdown, these frameshift mutations disrupted RAD51 IRIF formation (Figure 7D and data not shown). In addition, inactivation of RING-less BRCA1 resulted in dramatically increased sensitivity to both olaparib and cisplatin (Figure 7, E and F). These results were confirmed using another sgRNA targeting the Cas9 nuclease to exon 17 in the BRCA1-BRCT-encoding region of the Brca1185stop allele (Supplemental Figure 9, C–F).

To investigate whether disruption of the Brca1185stop allele also translates to a better treatment response in vivo, we performed orthotopic transplantation experiments in mice. The parental Kbi(185stop)P tumor cells and their Brca1-deficient subclone C3 grew into mammary tumors with a similar latency (data not shown), although untreated C3 tumors tended to proliferate at a somewhat slower rate once palpable (Supplemental Figure 10A). Strikingly, we also observed in vivo that inactivation of the Brca1185stop allele rendered Kbi(185stop)P tumor cells much more sensitive to PARP inhibition and cisplatin (Figure 7, G and H, and Supplemental Fig-
We used the PARP inhibitor AZD2461, which is a poor P-glycoprotein substrate, to avoid resistance caused by increased drug efflux (61). Mammary tumors derived from transplanted KBI(185stop)P cells only showed a moderate response to 28 days of treatment with AZD2461, with an increase of median survival from 21 to 32.5 days. In contrast, the median latency of tumors derived from the Brca1-knockout KBI(185stop)P clone C3 doubled from 35 to 72 days. Similarly, inactivation of the Brca1185stop allele resulted in a much more durable response to cisplatin. Two doses of cisplatin increased the median latency period for KBI(185stop)P outgrowths to 48 days, whereas mice bearing C3 tumors showed an increase in median survival out to 93 days. Thus, expression of RING-less BRCA1 variants can indeed lead to decreased sensitivity to HRD-targeted therapy.

Decreased sensitivity of BRCA1185delAG PDX tumors expressing RING-less BRCA1 to PARP1 inhibition. Although our data show that expression of RING-less BRCA1 can lead to HRD-targeted therapy resistance, it is not yet clear whether this is a relevant resistance mechanism in human cancer patients. To gain insight into the potential clinical relevance of RING-less BRCA1, we analyzed BRCA1 protein expression and olaparib response in 3 different BRCA1185delAG patient-derived xenograft (PDX) models of breast cancer. In one of these models, PDX179, we detected putative RING-less BRCA1 protein (Figure 8, A and B). Similar to SUM1315MO2 cells, PDX179 tumors expressed a nearly full-length BRCA1 variant that was not detected by an Ab raised against the BRCA1 N-terminus. In the 2 other BRCA1185delAG models, PDX127 and PDX230, we did not detect noticeable levels of RING-less BRCA1 expression. To investigate whether expression of RING-less BRCA1 would correlate with decreased sensitivity of BRCA1185delAG tumors to PARP inhibition, we performed olaparib treatment studies for all 3 PDX models (Figure 8C and Supplemental Figure 11, A–C). In line with the data from the KBI(185stop)P mouse model, PDX179 did not respond well to olaparib (Figure 8C and Supplemental Figure 11B). Thus, residual activity of RING-less BRCA1 may cause resistance to PARP inhibition in human tumors as well. The data for PDX127 illustrate that also BRCA1185delAG tumors with undetectable levels of (RING-less) BRCA1 expression may also show a poor response to treatment (Figure 8C and Supplemental Figure 11A), suggesting the existence of multiple mechanisms of resistance. Of note, similarly low expression levels of RING-less BRCA1 did not prevent regression of PDX230 tumors upon olaparib treatment (Figure 8C and Supplemental Figure 11C). We found no evidence of genetic reversion in any of the olaparib-resistant tumors (Figure 8, A and B, and data not shown). The results from the BRCA1185delAG PDX tumors support the data from our mouse models and tissue culture experiments and warrant a careful evaluation of response data from BRCA1185delAG breast and ovarian cancer patients treated with platinum drugs or PARP inhibitors.

Discussion

We have used genetically engineered mouse models mimicking the 2 most common BRCA1 founder mutations, BRCA1185delAG and BRCA15382insC, to study the effects of these mutations on tumor development and therapy response and resistance. While mice carrying the Brca1185stop or Brca15382insC mutation develop similar types of mammary carcinomas, Brca1185stop tumors respond significantly worse to HRD-targeted therapy than do Brca15382insC tumors and rapidly develop therapy resistance. It has previously been shown that secondary mutations in BRCA1 can mediate resistance to platinum-based chemotherapy in BRCA1185delAG ovarian carcinomas (59, 60). However, we could not detect genetic reversion of the Brca1185stop mutation in any of the platinum-resistant Brca1185stop
mouse mammary tumors. Also, in multiple cisplatin-resistant clones of the human BRCA1185delAG breast cancer cell line SUM1315MO2, no reversal of the mutation was found. Instead, we noticed that mouse and human BRCA1185delAG tumor cells produced RING-less BRCA1 proteins, which are involved in the development of platinum and PARP inhibitor resistance through their activity in the DNA damage response.

**A role for RING-less BRCA1 proteins in therapy response and resistance.** While it was thus far thought that the BRCA1185delAG frameshift mutation only leads to the formation of a small N-terminal protein of 38 aa, we detected nearly full-length, RING-less BRCA1 protein in Brca1185stop mouse mammary tumors. This was not merely an artifact of our genetically engineered mouse model, since we could also detect RING-less BRCA1 in human breast cancer cells carrying the BRCA1185delAG mutation.

*Brca1*185stop tumors did not require secondary *Brca1* mutations to become resistant to PARP inhibition or cisplatin, but residual activity of the RING-less BRCA1 protein was already sufficient to withstand these types of targeted therapeutics. This finding extends the conclusions of our previous work with *Brca1*185stop tumors, which expressed a full-length BRCA1 protein containing a missense mutation in the RING domain (43). Our data indicate that RING-less BRCA1 is not completely functional in HR, but that this protein still supports RAD51 IRIF formation. Thus, while insufficient for embryonic survival and tumor suppression, the residual activity of the RING-less BRCA1 protein can contribute to the rapid development of therapy resistance in *Brca1*185stop tumors. Our data suggest that there is no strict requirement for upregulation or stabilization of RING-less BRCA1 protein levels for resistance to occur. In both human and mouse breast cancer cells, RING-less BRCA1 supported RAD51 IRIF formation, demonstrating its functional significance. Moreover, deletion of the *Brca1*185stop allele rendered *Kbi*(185stop)P tumor cells sensitive to cisplatin and PARP inhibition. To further investigate the potential relevance of our findings for human cancer patients, we analyzed 3 independent *BRCA1*185delAG PDX models of breast cancer for expression of RING-less BRCA1 and response to PARP inhibition. In concordance with the data from our genetically engineered mouse models and the SUM1315MO2 cell line, a PDX model expressing RING-less BRCA1 showed progressive disease in the presence of the PARP inhibitor olaparib. Thus, human tumors expressing RING-less BRCA1 may also be resistant to HRD-targeted therapy. Although we detected no RING-less BRCA1 expression in another PDX model that showed resistance to olaparib, we found no evidence for genetic reversion of the *BRCA1*185delAG mutation in any of the PDX tumors.

Why, then, are secondary *BRCA1* mutations still observed in therapy-resistant *BRCA1*185delAG human ovarian carcinomas? One possibility is that these secondary *BRCA1* mutations are already present in rare cells of primary carcinomas, possibly because of genomic instability, and subsequently selected under the pressure of chemotherapy. This has been described before for chronic myeloid leukemia, in which BCR-ABL mutations that confer imatinib resistance are already present in a minority of tumor cells before exposure to the drug (65). In addition, the level of RING-less BRCA1 protein in untreated *BRCA1*185delAG human ovarian carcinomas is currently unknown. There could be considerable intertumoral heterogeneity in both the presence (and abundance) of preexisting secondary *BRCA1* mutations and the expression levels of RING-less BRCA1 protein. Furthermore, we observed substantial differences among tumors in the levels of RING-less BRCA1 expression, which may also exist between *BRCA1*185delAG breast and ovarian cancers. Genetic reversion might be the preferred mechanism of therapy resistance in tumors with preexisting secondary *BRCA1* mutations and weak or no expression of the RING-less BRCA1 protein.

The existence of RING-less BRCA1 proteins in mouse and human *BRCA1*185delAG tumor cells appears to be the result of internal translation reinitiation at downstream start codons, as has previously been observed in transient transfection experiments with human *BRCA1* minigenes (66). Translation initiation at methionine 297 of human BRCA1 could also explain why *BRCA1*185delAG mRNA is not degraded by NMD (66, 67). The mutant RING-less BRCA1 protein produced in our genetically engineered *Brca1*185stop mouse model is somewhat larger than its human counterpart, most likely because of usage of the more upstream alternative start codon at methionine 90 in the mouse *Brca1* coding sequence.

**Differences in therapy response between BRCA1 founder mutations.** While patients with *BRCA1*-mutated ovarian cancer have a better prognosis after platinum-based chemotherapy than do nonmutation carriers (15–18), some heterogeneity in survival appears to exist among carriers of different *BRCA1* mutations (16). Survival of ovarian cancer patients carrying the *BRCA1*185delAG mutation has been compared with that of *BRCA1*5382insC patients, but, unfortunately, no conclusions could be drawn because of the small number of patients with a *BRCA1*5382insC mutation (16). Our data indicate that the poor therapy response of *Brca1*185stop mouse mammary tumors is mediated by residual activity of the RING-less BRCA1 protein. Therefore, we predict that RING-less BRCA1 expression may also have consequences for the clinical response of *BRCA1*185delAG patients to DNA-damaging therapy.

Expression of a RING-less BRCA1 protein may not be limited to *BRCA1*185delAG tumors, but could also occur in tumors carrying other truncating mutations in the N-terminus of BRCA1. Our data suggest that the presence of a RING-less BRCA1 protein in these tumors can serve as a marker to predict poor response to treatment with platinum or PARP inhibitors. PARP inhibitors are currently being tested in phase III clinical trials for *BRCA1/2*-associated breast cancers and approved for advanced *BRCA1/2*-associated ovarian cancers. Although pathogenic germline mutations in *BRCA1* or *BRCA2* are thus far the best predictors of PARP inhibitor sensitivity, it will be important to critically evaluate the treatment response of tumors with mutations affecting the N-terminus of BRCA1. This type of analysis will require large numbers of patients carrying specific *BRCA1* founder mutations and therefore remains a challenge for the future. Meanwhile, our genetically engineered and PDX mouse models offer ideal platforms for testing hypotheses on therapy response and resistance. Knowledge gained from these models could contribute to more accurate predictions of therapy responses of different *BRCA1* mutation carriers, help to prevent ineffective treatment, and lead to earlier development and implementation of alternative therapeutic agents.
Methods

**Generation of Brca1\textsuperscript{185stop} and Brca1\textsuperscript{5382stop}-mutant mice.** Nonchemically modified deoxyribonucleotides (Sigma-Genosys) were used to introduce the \textit{Brca1}\textsuperscript{185stop} (5’-ATGCGAAAATCTCTAGATGGC-GATCTGGTAAGTCAAAC-3’) and \textit{Brca1}\textsuperscript{5382stop} (5’-CAAGGGCAGTC-CAGAGATCAGGACGGGAAAAGTAAAGTC-3’) mutations into mESCs. The procedures for the introduction of oligonucleotides into mESCs, selection for G418-resistant colonies, and identification and purification of modified cells have been described previously (44–47). The resulting ESCs were injected into C57BL/6j blastocysts to produce chimera mice, which were mated with FVB females to generate \textit{Brca1}\textsuperscript{185stop} and \textit{Brca1}\textsuperscript{5382stop} mice. \textit{Brca1}\textsuperscript{185stop} and \textit{Brca1}\textsuperscript{5382stop} mice were bred with K14-Cre \textit{Brca1}\textsuperscript{fl/fl} (KBIP) animals (48) to generate K14-Cre \textit{Brca1}\textsuperscript{185stop}\textsuperscript{fl/fl} [\textit{KB1(185stop)P}] and K14-Cre \textit{Brca1}\textsuperscript{5382stop}\textsuperscript{fl/fl} [\textit{KB1(5382stop)P}] mice. Full details on the generation of the \textit{Brca1}\textsuperscript{185stop} and \textit{Brca1}\textsuperscript{5382stop} alleles and mouse genotyping are provided in the Supplemental Methods.

**Embryo isolations.** Timed matings were performed between Brca1\textsuperscript{185stop} or Brca1\textsuperscript{5382stop} heterozygous male and female mice. The impregnated females were sacrificed at various time points after conception, and their uteri were isolated in ice-cold PBS. The embryos were isolated by removing the muscular wall of the uterus, Reichert’s membrane, and the visceral yolk sac. The visceral yolk sac was used for genotyping.

**Orthotopic transplantations and drug interventions.** Small fragments of mammary tumors from KP, KBIP, KBI(185stop)P, or KB1(5382stop)P mice were transplanted orthotopically into FVB:129/ Ola F1 hybrid female mice as described previously (55). To generate mouse mammary tumors from KB1(185stop)P cells, 500,000 cells were transplanted into the fourth right mammary fat pad of 9-week-old female athymic nude RjOrl:NMRI- Foxn1 nu/Foxn1nu mice. When the tumor volume exceeded 200 mm\textsuperscript{3}, the mice were treated with the maximum tolerated dose (MTD) of cisplatin, olaparib, or AZD2461 (23, 55, 61). To study resistance, animals received additional doses of cisplatin when tumors grew back to a size of 200 mm\textsuperscript{3}. Animals were sacrificed when the tumor volume exceeded 1,500 mm\textsuperscript{3} or when they became ill from drug toxicity.

The 3 PDx models used in this study were derived from PARP inhibitor-naïve \textit{BRCA1}\textsuperscript{3609-3611} carriers presenting with hormone receptor-negative, HER2-negative, triple-negative breast cancers (TNBCs). The patient from whom PDX179 was derived had received cisplatin prior to tumor implantation into nude mice. PDX127 and PDX179 were derived from metastatic lesions, and PDX230 was derived from a primary tumor (additional clinical history is provided in the Supplemental Information). Tumors were s.c. implanted into 6-week-old female athymic nude NOD-SCID mice (Envigo). Animals were supplemented with 1 μmol/l 17β-estradiol (Sigma-Aldrich) in their drinking water. Upon xenograft growth, tumor tissue was reimplanted into recipient mice, which were randomized for olaparib or vehicle treatment, starting at tumor volumes between 50 and 500 mm\textsuperscript{3}. Treatment consisted of either vehicle (10% v/v DMSO in 10% w/v Kleptose (Roquette Laisa España) [HP-β-CD] in purified, deionized water) or 50 mg/kg olaparib in vehicle, administered i.p. 5 days per week.

**Ribosome profiling of tumor cell lines.** Ribosome-protected RNA fragments were isolated and purified as described before (63), and libraries were sequenced on an Illumina HiSeq 2000 system. A detailed protocol is described in the Supplemental Methods.

**Mass spectrometric analysis of mouse RING-less BRCA1 protein.** Immunoprecipitated BRCA1 was subjected to nanoflow liquid chromatography–tandem mass spectrometry (LC-MS/MS) on an 1100 Series Capillary LC System (Agilent Technologies) coupled to an LTQ Orbitrap XL Mass Spectrometer (Thermo Fisher Scientific). Detailed information on the experimental procedures is provided in the Supplemental Methods.

**Sanger sequencing.** Sequencing was done using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). Sequencing was performed on both genomic DNA and cDNA from tumors and spleens. Primer information is provided in the Supplemental Methods.

**Array comparative genome hybridization and data analysis.** Genomic DNA samples from tumors and spleens were labeled with the NimbleGen Dual-Color DNA Labeling Kit and hybridized to the NimbleGen 12-plex 135K full-genome mouse custom NK1 array. Details of the analysis are described in the Supplemental Methods.

**Clonogenic survival assays.** Human and mouse cancer cell lines were plated onto 12-well plates at densities of 15,000 (SUM1315MO2, SUM149PT, HCC1957, and U87MB291); 6,000 (U2OS); and 600–1,000 (\textit{KB1(185stop)P}) cells per well, respectively. For comparisons of \textit{KB1(185stop)P}, KP, and KBIP cell lines, 1,000 \textit{KB1(185stop)P} and KP cells and 3,000 KBIP B11 cells were plated onto 6-well plates. Twelve hours to one day after plating, a range of concentrations of cisplatin (Sigma-Aldrich or Mayne Pharma) in saline or olaparib (AZD2281; Selleck Chemicals or AstraZeneca) in DMSO was added to the cells. Cells were also treated with only saline or DMSO as the “no-drug control.” Cells were allowed to grow in the presence of the drug for 7 days and stained with 0.1% to 1% crystal violet. Clonogenic survival was determined by measuring the absorbance of crystal violet at 590 to 595 nm. Full details on cell culture conditions are provided in the Supplemental Methods.

**BRCA1- and Brca1-knockdown experiments.** Cells were transduced with pLKO-puro shRNA viruses (TRC library clones; Thermo Scientific Open Biosystems) targeting human \textit{BRCA1} or mouse \textit{Brca1} or an NT control. After puromycin selection, cells were assayed for γ irradiation–induced DNA repair foci or seeded for clonal growth. SUM-1315MO2 cells were incubated with CellTiter-Blue (Promega) or fixed (2, 57, 64) to generate chimeric males, which were mated with FVB females to generate \textit{p53}fl/fl mice. Full details on the generation of the \textit{p53}fl/fl mice is provided in the Supplemental Methods.

**Crispr/Cas9-mediated inactivation of the Brca1\textsuperscript{185stop} allele.** CRISPR/Cas9 mutagenesis was performed as described previously (68). Briefly, \textit{KB1(185stop)P} mouse mammary tumor cells were transiently transfected with a modified pX330 CRISPR/Cas9 plasmid (Addgene plasmid 42230) containing a puromycin resistance marker and targeting the BKCT-encoding region of \textit{Brca1}. After 2 days of puromycin selection (1.8 μg/ml), cells were seeded at clonal density, and colonies were selected for further analyses and experiments. Full details are provided in the Supplemental Methods.

**Immunoblotting.** Tumor protein lysates were made by using a microhomogenizer and radioimmunoprecipitation assay (RIPA) lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.1% deoxycholate, 1% NP40), complemented with 2× Complete Protease Inhibitor Cocktail (Roche) and Pefabloc (Roche; 1 mg/ml). Following homogenization on ice, tumor lysates were kept on ice for 30 minutes. After a
short spin, protein concentrations were determined with the BCA Protein Assay Kit (Pierce, Thermo Fisher Scientific), and samples were prepared for gel electrophoresis. Western blotting was performed as described previously (69).

**Immunofluorescence analyses and IHC.** Immunofluorescence and IHC were essentially performed as described before (43, 70). For ex vivo analysis of RAD51 foci formation, cells from cryopreserved tumors were grown on glass coverslips for 36 to 48 hours, y irradiated with 10 Gy, and fixed 6 hours later in 2% paraformaldehyde. To quantify RAD51 foci in single tumor cells, 150–200 cells per condition were counted blindly. Cells were scored as RAD51 positive if they had more than 10 RAD51-positive dots per nucleus. For quantification of 53BP1 foci in formalin-fixed, paraffin-embedded (FFPE) sections of oolparib-treated mouse mammary tumors, at least 200 cells were counted using ImageJ software (NIH). Recruitment of RPA to 53BP1-positive DNA DSBs was analyzed using a particle irradiation through the bottom of a Mylar dish, as described by Stap et al. (71). A list of Abs and full procedures for immunohistochemical and immunofluorescence assays are provided in the Supplemental Methods.

**aCGH data.** aCGH data generated in this study have been deposited in the NCBI’s Gene Expression Omnibus (GEO) database (GEO GSE43997).

**Statistics.** Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software). Kaplan-Meier survival curves were compared using the log-rank test, contingency tables were compared using Fisher’s exact test, and other data were compared using 2-tailed t tests. A P value of less than 0.05 was considered significant, except when Bonferroni’s correction was applied to correct the significance threshold for multiple testing (P < 0.025 for Figure 6D, Figure 7, B, E, and F, Figure 8D, Supplemental Figure 7B, Supplemental Figure 9, E and F, and P < 0.01 for Supplemental Table 3D).

**Study approval.** All experiments involving genetically engineered mouse models complied with local and international regulations and ethics guidelines and were approved by the IACUC of the Netherlands Cancer Institute (DEC-NKI). For PDX tumors, patients’ consent for tumor use in animals was obtained under a protocol approved by the Vall d’Hebron Hospital Clinical Investigation Ethics Committee. Mice were maintained and treated in accordance with institutional guidelines, and experiments were approved by the IACUC of the Vall d’Hebron Institute of Research (VHIR Animal Use Committee).

**Author contributions**

RD, TT, PB, and JJ designed the study. RD, KKD, HvdG, IvDH, IB, CC, DC, MCB, UB, ES, EvdB, EW, MP, FLP, LvD, DHWD, and PB performed experiments. RD, KKD, IB, CC, CK, SK, FLP, RE, DHWD, and PB analyzed data. RD, SR, MvdV, JAAD, DCvG, RA, JB, VS, TT, PB, and J supervised experiments. RD, PB, and JJ wrote the manuscript, with input and scientific advice from VS and TT.

**Acknowledgments**

We thank the personnel of the NKI animal facility and the NKI Mouse Cancer Clinic transgenic facility and preclinical intervention unit for excellent help with the mouse experiments; the NKI animal pathology, digital microscopy, and genomics core facilities for expert help; M. O’Connor (AstraZeneca) for providing olaparib; R. Kanaar and A. Zelensky (Erasmus MC, Rotterdam, Netherlands) for the RAD51Ab and advice; R.I. Drapkin (University of Pennsylvania, Philadelphia, Pennsylvania, USA) for the polyclonal mouse BRCA1Ab; M. Schutte (Erasmus MC) and Paul Andreassen (Cincinnati Children’s Research Foundation, Cincinnati, Ohio, USA) for human breast cancer cell lines; M. Aarts, M. Dekker, S. de Vries, T. Harmsen, B. van den Broek, M. Barazas, P. ter Bruggie, K. Rooijers (all from the NKI), and Y.H. Ibrahim and M. Guzmán (from the Vall d’Hebron Institute of Oncology) for expert help and technical assistance. This work was supported by grants from the Dutch Cancer Society (NKI 2007-3772, to JJ, SR, and J. Schellens [all from the NKI]; NKI 2008-4116, to JJ and PB; NKI 2012-5220, to SR, and JJ; EMCR 2008-4045, to DCvG; NKI 2015-7877, to PB, J.J, and MPG Vreeswijk [Leiden University Medical Center, Leiden, The Netherlands]); the Netherlands Organization for Scientific Research (NWO) (Cancer Genomics Netherlands [CGCNI], Cancer Systems Biology Center [CSBC], Netherlands Genomic Initiative Zenith 93512009, to JJ, and NWO VICI 91814643, to JJ); the European Union Seventh Framework Programme (EurocanPlatform project 260791 and DDRresponse project 259893); the European Research Council (ERC) (CombatCancer ERC Synergy Project); a Ride for the Roses Cancer Research Grant (EMCR 2011-5030, to DvG); the Howard Hughes Medical Institute (to TT); the National Cancer Institute (NCI), NIH (R01 CA125636, to TT); and the NCI, NIH Chromosome Metabolism and Cancer Training Grant (T32 CA009657-21, to KD). KKD is a Thomsen Breast Cancer Fellow. Further support was provided by the Netherlands Proteomics Centre (NPC) and the Mouse Clinic for Cancer and Aging (MCCA), financed by the NWO as part of the National Roadmap for Large-Scale Research Facilities. Work at the Vall D’Hebron Institute of Oncology was supported by the Instituto de Salud Carlos III (PI12/02606, to JB) and the Asociación Española Contra el Cáncer (to CC).

Address correspondence to: Jos Jonkers or Peter Bouwman, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands. Phone: 0031. 20.5122000; E-mail: jjonkers@nki.nl (J. Jonkers), p.bouwman@nki.nl (P. Bouwman). Or to Toshiyasu Taniguchi, 1100 Fairview Ave. N., Cl-015 Seattle, Washington 98109-1024, USA. Phone: 206.667.7283; E-mail: ttaniguc@fhcrc.org.

9. Moschini R, et al. BRCA1 and BRCA2 muta-


59. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in
65. Roche-Lestienne C, et al. Several types of mutations of the Ab1 gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002;100(3):1014–1018.
66. Buisson M, Anczuków O, Zetoune AB, Ware MD, Mazoyer S. The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Hum Mutat. 2006;27(10):1024–1029.